Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Spero Therapeutics Inc SPRO

Healthcare Biotechnology
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with unmet need. Its lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease... see more

Recent & Breaking News (NDAQ:SPRO)

DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 25, 2022 in Spero Lawsuit - SPRO

Newsfile June 21, 2022

SPRO ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 25, 2022 in the Class Action Filed on Behalf of Spero Therapeutics, Inc. Shareholders

PR Newswire June 21, 2022

SPRO ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 25, 2022 in the Class Action Filed on Behalf of Spero Therapeutics, Inc. Limited Shareholders

Newsfile June 20, 2022

SPRO INVESTOR NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SPRO

PR Newswire June 20, 2022

DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 25, 2022 in Spero Lawsuit - SPRO

Newsfile June 20, 2022

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Spero Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile June 20, 2022

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Spero Investors of a Lead Plaintiff Deadline of July 25, 2022

PR Newswire June 20, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spero Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SPRO

PR Newswire June 20, 2022

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Spero Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Accesswire June 17, 2022

SPRO Investors Have Opportunity to Lead Spero Therapeutics, Inc. Securities Fraud Lawsuit

PR Newswire June 17, 2022

SPRO SHAREHOLDER ALERT: Jakubowitz Law Reminds Spero Shareholders of a Lead Plaintiff Deadline of July 25, 2022

PR Newswire June 17, 2022

ROSEN, A LEADING LAW FIRM, Encourages Spero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRO

Newsfile June 16, 2022

SPRO ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 25, 2022 in the Class Action Filed on Behalf of Spero Therapeutics, Inc. Limited Shareholders

Newsfile June 16, 2022

Spero Therapeutics, Inc. Investor News: Robbins LLP is Investigating Spero Therapeutics, Inc. (SPRO) on Behalf of Shareholders

Business Wire June 16, 2022

SPRO LAWSUIT ALERT: Levi & Korsinsky Notifies Spero Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

PR Newswire June 16, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spero Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SPRO

Newsfile June 15, 2022

SPRO Investors Have Opportunity to Lead Spero Therapeutics, Inc. Securities Fraud Lawsuit

PR Newswire June 15, 2022

Spero Class Action: Levi & Korsinsky Reminds Spero Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 25, 2022 - SPRO

Newsfile June 15, 2022

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Spero Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile June 15, 2022

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Spero Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 25, 2022 - (NASDAQ: SPRO)

PR Newswire June 15, 2022